A Case Report of a Hemodialysis Patient With Coagulation Factor XI and Factor XII Deficiencies.
Factor XI deficiency
Factor XII deficiency
case report
hemodialysis
low‐molecular‐weight heparins
Journal
Seminars in dialysis
ISSN: 1525-139X
Titre abrégé: Semin Dial
Pays: United States
ID NLM: 8911629
Informations de publication
Date de publication:
18 Aug 2024
18 Aug 2024
Historique:
revised:
26
06
2024
received:
16
04
2024
accepted:
12
07
2024
medline:
19
8
2024
pubmed:
19
8
2024
entrez:
18
8
2024
Statut:
aheadofprint
Résumé
Coagulation Factor XI (FXI) and Factor XII (FXII) deficiencies are rare. FXI deficiency is associated with a bleeding disorder, while FXII deficiency is not, but both can cause chronic prolongation of activated partial thromboplastin time and impair thrombus formation, posing great challenges for hemodialysis anticoagulation. Traditionally, heparin or low-molecular-weight heparins (LMWHs) are not considered a safe anticoagulation option for patients with increased bleeding risk. In this context, FXI and FXII have received substantial attention as targets for new anticoagulants. We present the case of a 68-year-old woman with combined FXI and FXII deficiencies who successfully underwent hemodialysis with anticoagulation using a low dose of LMWHs. This case highlights that FXI and FXII deficiencies are associated with anticoagulant effects, which can reduce the dosage of anticoagulant during hemodialysis. With careful monitoring, an appropriate dosage of LMWHs is still an acceptable option for patients with a bleeding risk.
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
E. G. Pavlou, H. T. Georgatzakou, S. P. Fortis, et al., “Coagulation Abnormalities in Renal Pathology of Chronic Kidney Disease: The Interplay Between Blood Cells and Soluble Factors,” Biomolecules 11 (2021): 1309, https://doi.org/10.3390/biom11091309.
F. Müller, D. Gailani, and T. Renné, “Factor XI and XII as Antithrombotic Targets,” Current Opinion in Hematology 18 (2011): 349–355, https://doi.org/10.1097/MOH.0b013e3283497e61.
T. Li, J. Liu, W. Wu, and X. I. Factor, “A Potential Target for Anticoagulation Therapy for Venous Thromboembolism,” Frontiers in Cardiovascular Medicine 9 (2022): 975767, https://doi.org/10.3389/fcvm.2022.975767.
C. Maas and T. Renné, “Coagulation Factor XII in Thrombosis and Inflammation,” Blood 131 (2018): 1903–1909, https://doi.org/10.1182/blood‐2017‐04‐569111.
C. Kleinschnitz, G. Stoll, M. Bendszus, et al., “Targeting Coagulation Factor XII Provides Protection From Pathological Thrombosis in Cerebral Ischemia Without Interfering With Hemostasis,” Journal of Experimental Medicine 203 (2006): 513–518, https://doi.org/10.1084/jem.20052458.
T. Renné, M. Pozgajová, S. Grüner, et al., “Defective Thrombus Formation in Mice Lacking Coagulation Factor XII,” Journal of Experimental Medicine 202 (2005): 271–281, https://doi.org/10.1084/jem.20050664.
D. Gailani, “New Insights Into Factor XI Function: From Biochemistry to Animal Models BLOOD,” 116 (2023): SCI‐20, https://doi.org/10.1182/blood.v116.21.sci‐20.sci‐20.
J. I. Weitz, “Factor XI and Factor XII as Targets for New Anticoagulants,” Thrombosis Research 141 (2016): S40–S45, https://doi.org/10.1016/S0049‐3848(16)30363‐2.
J. I. Weitz and N. C. Chan, “Novel Antithrombotic Strategies for Treatment of Venous Thromboembolism,” Blood 135 (2020): 351–359, https://doi.org/10.1182/blood.2019000919.
M. Walsh, C. Bethune, A. Smyth, et al., “Phase 2 Study of the Factor XI Antisense Inhibitor IONIS‐FXIRx in Patients With ESRD,” Kidney International Reports 7 (2022): 200–209, https://doi.org/10.1016/j.ekir.2021.11.011.
Y. Takamizawa, M. Araki, N. Yoshida, T. Yoshioka, and K. Miura, “A Case of a Severe Factor XI Deficiency in Patient Undergoing Hemodialysis Without the Use of Heparin,” Blood Coagulation & Fibrinolysis 25, no. 8 (2014): 898–899, https://doi.org/10.1097/MBC.0000000000000151.
X. Li, M. Chen, Y. Wang, et al., “Successful Use of Peritoneal Dialysis After Abdominal Surgery in a Patient With Factor XI Deficiency: A Case Report,” Seminars in Dialysis 36 (2023): 178–182, https://doi.org/10.1111/sdi.13136.
A. Davenport, “What Are the Anticoagulation Options for Intermittent Hemodialysis?” Nature Reviews Nephrology 7 (2011): 499–508, https://doi.org/10.1038/nrneph.2011.88.
C. Leroy, B. Pereira, E. Soum, et al., “Comparison Between Regional Citrate Anticoagulation and Heparin for Intermittent Hemodialysis in ICU Patients: A Propensity Score‐Matched Cohort Study,” Annals of Intensive Care 11 (2021): 13, https://doi.org/10.1186/s13613‐021‐00803‐x.